Drug approved for symptomatic vitreomacular adhesion

October 19, 2012
Drug approved for symptomatic vitreomacular adhesion

(HealthDay)—Jetrea (ocriplasmin) has been approved by the U.S. Food and Drug Administration to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

The condition affects the vitreous, which begins to separate from the macula. This can damage the macula, a key part of the eye's retina that's responsible for people being able to read, the FDA said Thursday in a news release.

Jetrea helps break down proteins that are responsible for VMA, preventing the need for surgery to control the condition, the agency said.

In a clinical study of 652 people, VMA resolved in 26 percent of those who took Jetrea, compared to 10 percent of cases that were resolved among those who took an inactive placebo.

The most common side effects of Jetrea were including: bleeding, pain, floaters, blurriness, vision loss, and swelling.

Jetrea is produced by ThromboGenics, based in Iselin, N.J.

Explore further: Vitreolytic ocriplasmin resolves vitreomacular traction

More information: The FDA has more about this approval.

Related Stories

Vitreolytic ocriplasmin resolves vitreomacular traction

August 16, 2012

(HealthDay) -- Intravitreal injection of the vitreolytic agent ocriplasmin resolves vitreomacular traction and closes macular holes significantly better than placebo, but with a higher incidence of adverse events, according ...

FDA approves drug to treat diabetic macular edema

August 13, 2012

The U.S. Food and Drug Administration today announced its approval of Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, or DME, an eye condition in people with diabetes that causes blurred vision, ...

Glaucoma stent approved

June 26, 2012

(HealthDay) -- An ocular stent that's designed to reduce inner-eye pressure among people with mild or moderate open-angle glaucoma has been approved by the U.S. Food and Drug Administration.

FDA approves Regeneron's eye injection Eylea

November 19, 2011

(AP) -- Regulators on Friday approved Regeneron Pharmaceuticals Inc.'s drug Eylea, an injection designed to treat a common cause of blindness in older people.

Recommended for you

Researchers identify drug that alleviates opioid withdrawal

January 30, 2017

Opioid use and abuse is a significant social, health and economic issue in Canada. Researchers at the University of Calgary's Faculty of Veterinary Medicine (UCVM) and Hotchkiss Brain Institute (HBI) have discovered that ...

Detecting counterfeit medicines

January 27, 2017

Bernard Naughton and Dr David Brindley from Oxford University's Saïd Business School and Medical Sciences Division discuss the problems of identifying fake, substandard and expired medicines.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.